Skip to content

Zoetis ZTS Restructuring Charges

Restructuring Charges at other companies

Merck & Co. logo
Merck & Co.MRK
$195M+183%
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$30.13B-57.0%
Enterprise value$38.17B-49.3%
P/E11.4×-15.7×
P/S3.2×-4.3×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's restructuring charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's restructuring charges?
Zoetis (ZTS) reported restructuring charges of $20M in Q1 2026.
What does restructuring charges mean?
One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.